NICE(UK): Belantamab mafodotin plus pomalidomide and dexamethasone can be used as an option to treat multiple myeloma in adults, if: i) they have only had 1 line of treatment… read more.
PROCEPT BioRobotics highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy… read more.
The FDA approved Boehringer Ingelheim’s Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase… read more.
Abbott announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using… read more.
Hansa Biopharma AB announced that the FDA has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User… read more.
NICE(UK): Molnupiravir is recommended as an option for treating mild to moderate COVID‑19 in adults who have a positive SARS‑CoV‑2 test, only if: i) they have 1 or… read more.
Celltrion Inc. announced that Avtozma (tocilizumab-anoh) subcutaneous (SC) formulation is now available to patients in the United States. With this launch, Celltrion’s Avtozma becomes one of the first tocilizumab… read more.
Novartis announced today that Cosentyx (secukinumab) received FDA approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population. The… read more.
NICE(UK): Dupilumab, as an add-on to intranasal corticosteroids, can be used as an option to treat severe chronic rhinosinusitis with nasal polyps in adults if: i) the condition… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) from Sun Pharma UK Ltd. to treat severe alopecia areata in adults. Approval was based on… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending the granting of a marketing authorisation for Poherdy in combination with trastuzumab and… read more.
Vertex Pharmaceuticals Incorporated announced data from a Phase IV study of Journavx (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
